Scientists test new drug duo in fight against blood cancer
NCT ID NCT05971251
Summary
This early-stage study is testing a new combination of two drugs, loncastuximab tesirine and acalabrutinib, for people with chronic lymphocytic leukemia (CLL). The main goal is to find the safest and most effective dose of the loncastuximab drug when added to the standard acalabrutinib treatment. The study will enroll about 24 participants who have CLL that has come back or stopped responding to prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.